Zhongchao Inc. (ZCMD) AI Stock Analysis

Established in 2012 and headquartered in Shanghai, China, Zhongchao Inc. delivers healthcare information, education, and training programs for medical personnel across the People's Republic of China. The company operates through its MDMOOC online platform at mdmooc.org, which provides clinical practice training, interactive case studies, academic workshops, and continuing education. It also generates tailored educational courses for enterprises, non-profit entities, and medical journals. Additionally, Zhongchao offers patient management services through its Zhongxun platform and operates Sunshine Health Forums across WeChat subscription accounts and a mobile app to facilitate community engagement and knowledge sharing among healthcare professionals.

Zhongchao has experienced volatile top-line results, reflected in a 5-year revenue CAGR of -8.8% between FY2020 and FY2025. After revenue reached $19.4M in FY2023, it declined 18.4% to $15.9M in FY2024 and dropped further by 28.3% to $11.4M in FY2025. Net income fell from -$643,229 in FY2024 to -$6.3M in FY2025, while gross margin decreased from 56.2% to 42.5%. Operating margin stood at -54.4% in FY2025. For the trailing twelve months ended March 31, 2026, revenue was $11.4M with a net profit margin of -55.5% and an operating margin of -92.0%. In the quarter ended March 31, 2026, quarterly revenue fell 23.2% year-over-year, and earnings declined 91.0%.

As of March 31, 2026, Zhongchao reported $13.9M in cash and short-term investments alongside total debt of $26,083, creating a net cash balance of $13.9M. Total assets stood at $24.3M against shareholders' equity of $18.6M. Liquidity remained solid with a current ratio of 11.11 and a debt-to-equity ratio of 0.00. In FY2025, operating cash flow reached $845,391 and capital expenditures totaled $152,561, generating free cash flow of $692,830. Over the past five years, the company's share count changed by -99.8%.

At a last close of $1.31 on October 16, 2026, Zhongchao had a market capitalization of $5.8M and an enterprise value of -$5.1M. The stock trades at a price-to-sales multiple of 0.5x, well below the 4.1x median of its US-listed Healthcare peers. Its price-to-book ratio is 0.5x, while its enterprise value to EBITDA ratio is 107.1x, compared to the peer median of 12.0x. Over the past year, ZCMD posted a return of -99.9%, compared to a 16.8% return for the S&P 500 benchmark SPY. Over five years, the stock fell 100.0% while SPY gained 83.0%.

Wall Street analyst coverage for Zhongchao is limited, with no consensus price target or formal recommendation tracking available. Over the last four quarters, the company recorded 1 EPS beat. Trailing twelve months earnings per share stood at -$344.10 as of March 31, 2026. Institutional ownership is 0.0%, while insider holdings represent 28.9% of shares and short interest accounts for 5.0% of the float.

This page is an AI-written research summary of Zhongchao Inc. (ZCMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ZCMD income statement, ZCMD balance sheet, ZCMD key metrics, ZCMD chart. See the ZCMD stock overview for the latest quote and news.